期刊文献+

荷瘤乳腺癌女性外周血髓样来源抑制性细胞表达浓度及意义分析

Expression Concentration of Myeloid-derived Suppressor Cells in Peripheral Blood of Tumor-bearing Females With Breast Cancer and the Significance Analysis
下载PDF
导出
摘要 目的:分析荷瘤乳腺癌女性外周血髓样来源抑制性细胞(MDSC)表达浓度及意义。方法:连续选取2015年1月至2016年12月经我院肿瘤外科初次确诊的女性乳腺癌患者41例,入选对象均未接受过各种治疗。对照组选择同期参加我院医院体检结论健康志愿者26例。乳腺癌组在开始治疗前接受了外周血MDSC(CD11b+、CD33+、CD14-)表达浓度检测,对照组在体检期间接受了相同检查。结果:荷瘤乳腺癌女性患者外周血MDSC表达浓度明显高于对照组,不同年龄荷瘤乳腺癌女性外周血MDSC表达浓度均明显高于相同年龄对照组(P均<0.001)。不同临床表现荷瘤乳腺癌女性外周血MDSC表达浓度比较中,肿瘤淋巴结转移(TNM)Ⅲ期组外周血MDSC表达浓度明显高于TNMⅠ期和Ⅱ期组(P<0.01),而年龄小组与年龄大组外周血MDSC表达浓度分布无明显区别(P>0.05)。不同病理情况荷瘤乳腺癌女性外周血MDSC表达浓度比较中,淋巴结转移组外周血MDSC表达浓度明显高于无淋巴结转移组(P<0.01),而肿瘤体积小组与肿瘤体积大组、组织学Ⅰ级和Ⅱ级组与组织学Ⅲ级组外周血MDSC表达浓度分布均无明显区别(P均>0.05)。不同分子学分型荷瘤乳腺癌女性外周血MDSC表达浓度比较中,Luminal A、Luminal B、HER-2过表达型和三阴乳腺癌等分子学分型荷瘤乳腺癌女性外周血MDSC表达浓度分布均无明显区别(P均>0.05)。结论:外周血MDSC可作为乳腺癌生物学辅助诊断特异性标识,且与乳腺癌临床TNM分期以及有无淋巴结转移关系密切。 Objective: To analyze the expression and significance of myeloid-derived suppressor cells(MDSCs) in the peripheral blood of tumor-bearing females with breast cancer. Methods: 41 female patients who were firstly diagnosed as breast cancer by the department of tumor surgery in our hospital were successively selected from January 2015 to December 2016,and all the enrolled subjects did not accept any treatments. 26 volunteers were selected as the control group from the physical examinees who were concluded as healthy during the same period. The patients in the breast cancer group accepted the detection of the expression concentrations of MDSCs(CD11 b^+,CD33^+and CD14^-) in the peripheral blood before treatment,and the subjects in the control group accepted the same detection during the physical examination. Results: The expression concentrations of MDSCs in the peripheral blood of tumor-bearing female patients with breast cancer were obviously higher than those in the control group,and the the expression concentrations of MDSCs in the peripheral blood of tumor-bearing females of different ages were all obviously higher than those in the control groups of the same ages(P all 0. 001). The expression concentrations of MDSCs in the peripheral blood in the tumor node metastasis(TNM) Stage Ⅲ group were obviously higher than those in the TNM StageⅠandⅡgroup(P〈0. 01),whereas there were no significant differences in the distribution of theexpression concentrations of MDSCs in the peripheral blood between the younger group and the older group(P〈0. 05). The expression concentrations of MDSCs in the peripheral blood in the TNM group were obviously higher than those in the non-TNM group(P〈0. 01),whereas the distributions of the expression concentrations of MDSCs in the peripheral blood in the small tumor volume group had no significant differences from those in the big tumor volume group,histological StageⅠgroup,histological StageⅡgroup and histological Stage Ⅲ group(P all
出处 《中国医药导刊》 2017年第10期993-996,共4页 Chinese Journal of Medicinal Guide
基金 辽宁省2011年科学技术计划资助项目(项目编号:2011225019 项目名称:高发恶性肿瘤防治技术研究与临床评价)
关键词 乳腺癌/荷瘤 髓样来源的抑制性细胞/外周血 临床分期 病理特征 Breast cancer/tumor-bearing Myeloid-derived suppressor cells(MDSCs)/peripheral blood Clinical stages Pathological characteristics
  • 相关文献

参考文献4

二级参考文献84

  • 1Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J] .Ca Cancer J Clin,2010,60(5):277-300. 被引量:1
  • 2Ugel S,Delpozzo F,Desantis G,et al.Therapeutic targeting of myeloid-derived suppressor cells[J] .Curr Opin Pharmacol,2009,9(4):470-481. 被引量:1
  • 3Ko JS,Zea AH,Rini BI,et al.Sunitinib mediates reersal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients[J] .Clin Cancer Res,2009,15(6):2148-2157. 被引量:1
  • 4Diaz-Montero CM,Salem ML,Nishihimura MI,et al.Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage,metastatic tumor burden,and doxorubicin-cyclophosphamide chemotherapy[J] .Cancer Immunol Immunother,2009,58 (1):49-59. 被引量:1
  • 5Joshi M,Ayoola A,Belani CP.Small-cell lung cancer:an update on targeted therapies[J] .Adv Exp Med Biol,2013,779:385-404. 被引量:1
  • 6Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J] .Nat Rev Cancer,2012,12(4):252-264. 被引量:1
  • 7Finke J,Ko J,Rini B,et al.MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy[J] .Int Immunopharmacol,201 1,11 (7):856-861. 被引量:1
  • 8Tartour E,Pere H,Maillere B,et al.Angiogenesis and immunity:a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy[J] .Cancer Metastasis Rev,2011,30(1):83-95. 被引量:1
  • 9Talmadge JE.Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy[J] .Clin Cancer Res,2007,13 (18 Pt 1):5243-5248. 被引量:1
  • 10Rodriguez PC,Ochoa AC.Arginine regulation by myeloid derived suppressor cells and tolerance in cancer:mechanisms and therapeutic perspectives[J] .Immunol Rev,2008,222:180-191. 被引量:1

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部